4577.T
Latest Trade
3,190.00JPYChange
35.00(+1.11%)Volume
21,800Today's Range
-
3,190.0052 Week Range
-
3,750.00As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 3,155.00 |
|---|---|
Open | 3,160.00 |
Volume | 21,800 |
3M AVG Volume | 0.58 |
Today's High | 3,190.00 |
Today's Low | 3,135.00 |
52 Week High | 3,750.00 |
52 Week Low | 2,688.00 |
Shares Out (MIL) | 12.66 |
Market Cap (MIL) | 39,950.07 |
Forward P/E | 11.28 |
Dividend (Yield %) | 1.20 |
Medical System Network unit says business alliance with Daito Pharmaceutical
Daito Pharmaceutical to build new building for pharmaceutical production
Daito Pharmaceutical says Yoshihiro Narai to resign as chairman
Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the pharmaceutical ingredients and formulation business, as well as healthy food. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.
Industry
Biotechnology & Drugs
Executive Leadership
Yasunobu Ohtsuga
President, Representative Director
Junichi Kikuta
Senior Managing Director
Mitsuo Hirono
Managing Executive Officer, Chief Director of Purchasing & Logistics
Masuo Nomura
Managing Executive Officer, Chief Director of Administration, Manager of Business Planning Office
Masamichi Takimoto
Managing Executive Officer, Chief Director of Pharmaceuticals
Price To Earnings (TTM) | 10.81 |
|---|---|
Price To Sales (TTM) | 0.93 |
Price To Book (MRQ) | 1.25 |
Price To Cash Flow (TTM) | 6.10 |
Total Debt To Equity (MRQ) | 14.16 |
LT Debt To Equity (MRQ) | 8.48 |
Return on Investment (TTM) | 10.70 |
Return on Equity (TTM) | 7.58 |
* Says Sapporo-based pharmaceutical unit forms business alliance with Daito Pharmaceutical Co Ltd on Feb. 16, and mainly cooperate on provision of joint developed drug
* Says it will build a new building for pharmaceutical production in October and invest 3.5 billion yen
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.